Sign up for free insights newsletter
FM

Fresenius Medical Care AG & Co. KGaA

FMCQFUnited States

Need professional-grade analysis? Visit stockanalysis.com

$49.21
+0.00%
End of day
Market Cap

$17.53B

P/E Ratio

14.55

Employees

109,698

Dividend Yield

3.31%

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino3.95-0.081.65
Calmar7.75-0.103.26
Sharpe1.20-0.060.48
Omega2.861.051.82
Martin11.59-0.144.89
Ulcer2.1814.809.39

Fresenius Medical Care AG & Co. KGaA (FMCQF) Price Performance

Fresenius Medical Care AG & Co. KGaA (FMCQF) trades on United States in USD. The company is classified in the Healthcare sector under the Medical Care Facilities industry. The stock currently trades at $49.21.

Over the past year, FMCQF has traded between a low of $44.71 and a high of $60.07. The stock has gained 3.2% over this period. It is currently 18.1% below its 52-week high.

Fresenius Medical Care AG & Co. KGaA has a market capitalization of $17.53B, with a price-to-earnings ratio of 14.55 and a dividend yield of 3.31%.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Company Info

Exchange
United States
Currency
USD

Financial Metrics

Revenue (TTM)
$19.63B
EBITDA
$2.62B
Profit Margin
4.99%
EPS (TTM)
3.85
Book Value
54.62

Technical Indicators

52 Week High
$60.07
52 Week Low
$44.71
50 Day MA
$46.75
200 Day MA
$50.67
Beta
0.94

Valuation

Trailing P/E
14.55
Forward P/E
9.92
Price/Sales
0.89
Price/Book
0.89
Enterprise Value
$24.08B